Another Bay Area biotech jumps in to fight coronavirus

As Gilead's potential Covid-19 treatment starts a National Institutes of Health clinical trial in Nebraska, this young San Francisco biotech with a library of antibodies is collaborating with an established biotech company in China.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.